Crispr Therapeutics AG stock kpis
Want to see CRSP full AI Analyst Report?
Operating Expense Breakdown
Crispr Therapeutics AG reported operating expenses of $124.98M in Q2 2026, down 5.1% from Q1 2026 and down 6.7% year over year. The highest value was $183.42M in Q2 2022.
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.
CRSP is moving spend away from steady internal R&D toward increasingly large, lumpy collaboration payments; R&D has eased from its 2022 peak while collaboration outlays have become the main driver of operating volatility, with G&A staying controlled. That pattern implies the company is leaning on partners and milestone-driven programs to advance assets—which can speed development and de‑risk costs but raises cash‑flow unpredictability and a potential long‑term risk if in‑house discovery is deprioritized.
CRSP Operating Expense Breakdown
| Period | Research and Development | General and Administrative | Collaboration | Total |
|---|---|---|---|---|
| Q2 2026Jun 30, 2026 | $67.15M | $17.55M | $40.27M | $124.98M |
| Q1 2026Mar 31, 2026 | $68.57M | $17.18M | $45.95M | $131.71M |
| Q4 2025Dec 31, 2025 | $83.53M | $18.40M | $53.70M | $155.63M |
| Q3 2025Sep 30, 2025 | $58.90M | $16.93M | $57.12M | $132.95M |
| Q2 2025Jun 30, 2025 | $69.89M | $18.92M | $45.15M | $133.96M |
| Q1 2025Mar 31, 2025 | $72.48M | $19.30M | $57.51M | $149.29M |
| Q4 2024Dec 31, 2024 | $82.16M | $18.12M | $10.42M | $110.70M |
| Q3 2024Sep 30, 2024 | $82.16M | $17.42M | $11.15M | $110.73M |
| Q2 2024Jun 30, 2024 | $80.17M | $19.48M | $52.13M | $151.78M |
| Q1 2024Mar 31, 2024 | $76.17M | $17.95M | $46.97M | $141.09M |
| Q4 2023Dec 31, 2023 | $95.14M | $16.48M | $20.00M | $131.62M |
| Q3 2023Sep 30, 2023 | $90.70M | $18.29M | $23.42M | $132.41M |
| Q2 2023Jun 30, 2023 | $101.56M | $19.03M | $44.64M | $165.22M |
| Q1 2023Mar 31, 2023 | $99.94M | $22.36M | $42.19M | $164.49M |
| Q4 2022Dec 31, 2022 | $103.56M | $21.17M | $6.82M | $131.55M |
| Q3 2022Sep 30, 2022 | $116.62M | $27.00M | $38.86M | $182.48M |
| Q2 2022Jun 30, 2022 | $123.22M | $26.27M | $33.92M | $183.42M |
| Q1 2022Mar 31, 2022 | $118.25M | $28.02M | $30.65M | $176.91M |
| Q4 2021Dec 31, 2021 | $103.09M | $23.68M | $31.82M | $158.60M |
| Q3 2021Sep 30, 2021 | $83.50M | $23.71M | $22.46M | $129.67M |
| Q2 2021Jun 30, 2021 | $82.33M | $28.81M | $26.95M | $138.08M |
| Q1 2021Mar 31, 2021 | $70.62M | $24.52M | $19.95M | $115.08M |
| Q4 2020Dec 31, 2020 | $82.36M | $25.77M | $0.00 | $108.13M |
| Q3 2020Sep 30, 2020 | $71.01M | $21.54M | $0.00 | $92.55M |
| Q2 2020Jun 30, 2020 | $59.38M | $21.35M | $0.00 | $80.73M |
| Q1 2020Mar 31, 2020 | $54.19M | $19.55M | $0.00 | $73.74M |
| Q4 2019Dec 31, 2019 | $48.76M | $17.27M | $0.00 | $66.03M |
| Q3 2019Sep 30, 2019 | $57.25M | $15.52M | $0.00 | $72.77M |
| Q2 2019Jun 30, 2019 | $39.53M | $15.77M | $0.00 | $55.30M |
| Q1 2019Mar 31, 2019 | $33.82M | $14.93M | $0.00 | $48.75M |
| Q4 2018Dec 31, 2018 | $28.80M | $16.54M | $0.00 | $45.34M |
| Q3 2018Sep 30, 2018 | $39.80M | $10.20M | $0.00 | $50.00M |

